Marvin C. Gershengorn, M.D. is Chief of the NIDDK's Laboratory of Endocrinology and Receptor Biology and Section Chief of the Receptor and Hormone Action Section
3/25/2019 · I conduct studies on the structure-function relationships of G protein-coupled receptors—in particular, receptors for thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH). An important aspect of this research is to discover small molecule ligands for these receptors that can ...
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK conducts and supports research on many of the most common, costly, and chronic conditions to improve health. Learn more
Gershengorn To Direct Intramural NIDDK. Dr. Marvin C. Gershengorn will direct the Division of Intramural Research in the National Institute of Diabetes and Digestive and Kidney Diseases in spring 2001. His appointment marks a return to NIDDK, where he worked 25 years ago as a …
1/12/2018 · 1964 1964. Drs. Harvey Alter, Clinical Center, and Baruch Blumberg, NIDDK, codiscover the Australian antigen, which Blumberg later shows to be the surface coating of the hepatitis B virus, leading to the isolation of this medically important virus.
3/7/2007 · According to Dr. Griffin Rodgers, acting director of NIDDK and co-chair of the NIH obesity research task force, the unit is an example of “syzygy,” a term often used to describe the alignment of celestial bodies, because so many disparate elements blended in the new space.
I n 1955, the National Institute of Arthritis and Metabolic Diseases, the predecessor of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), established the Clinical Endocrinology Branch (CEB). 1 A multidisciplinary group of scientists were brought together to collaborate in the study of the physiology and diseases of the thyroid gland.
9/1/2009 · In this report, we describe the discovery and SAR studies of a series of dihydroquinazolin-4-ones as TSHR agonists. ML109 (CID-25246343) is the first selective and orally available small-molecule TSHR agonist, and the probe will be a useful pharmacological tool to study TSHR biology in thyroidal and extrathyroidal tissues.
Susanne Neumann of National Institutes of Health, MD (NIH) | Read 96 publications, and contact Susanne Neumann on ResearchGate, the professional network for scientists.
U: This study . will be beginning. It will be led by NHLBI, with additional collaborative support from NIDDK. UHEALTHY Study (-$12 millio n; total $10.5 million) U: For this school-based study of ways . to reduce risk factors for type 2 diabetes, the intervention will be completed during FY 2009, and follow-up data analysis will be less expensive.
Endocrine: ENDO-1: Deak, Andrea Marques (NIMH) A.H.M. Deak, S. Meftah, P. Martinez, F. Eskandari, S. Torvik, S. Mistry, D. Ronsaville, J. Reynolds, E. Sternberg and F ...
A Phase I Study Of Hepatic Arterial Melphalan Infusion And Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters In Patients With Unresectable Hepatic Malignancies ... Marvin C. (NIDDK) M.C. Gershengorn, A.A. Hardikar, C. Wei, E. Geras-Raaka, B. Marcus-Samuels, B.M. Raaka : Epithelial-to-Mesenchymal Transition Generates ...
J Gershengorn's 7 research works with 224 citations including: Sleep Extension Improves Neurocognitive Functions in Chronically Sleep-Deprived Obese Individuals.
Total, NIDDK 638 1,853,149 646 1,854,283 655 1,858,045 9 3,762 Includes FTEs which are reimbursed from the NIH Roadmap for Medical Research NATIONAL INSTITUTES OF HEALTH National Institute of Diabetes and Digestive and Kidney Diseases (Dollars in Thousands) Budget Mechanism - Total FY 2006 Actual FY 2007 Continuing Resolution
Genomics Study Specifications Study Name S erum s ta vio nf c h Il - d Precursor Cells Contact Name Marvin Gershengorn (NIDDK Intramural) Publication Not provided My Strategies Return to My Strategies page Classification Cell differentiation; Differentiation of insulin-producing cells Links B iom ate rlsG ph ArrayExpress BCBC Release Date July ...
"GPCRs are the targets of roughly a third of medicines sold today, so if this finding for TRH holds for other GPCR targets, it could have significant implications for drug development," says Dr. Marvin C. Gershengorn, director of NIDDK's Division of Intramural Research and senior author of the paper.
"We are set up to study human metabolism in a way that we were never able to do before," says Marvin Gershengorn, NIDDK scientific director, who describes the unit as a melding of the fields of metabolism, endocrinology, nutrition, cardiovascular biology, gastroenterology, hepatology, genetics, and …
View Notes - Council_Minutes_Jan_2008_final.doc from HLTH 202 at Montclair State University. Meeting Minutes Department of Health and Human Services National Institutes of Health National Diabetes
In Drug Design, a Loose Fit May Be Best Bet. ... asthma, migraine, and pain. The study is published in the May 12, ... it could have significant implications for drug development,” says Marvin C. Gershengorn, M.D., director of NIDDK’s Division of Intramural Research and senior author of the paper.
CC celebrates Valentine’s Day Second couple hits 100 blood donations Ribbon-cutting, open house introduce new Metabolic Clinical Research Unit The new NIH Metabolic Clinical Research Unit, which houses specialized, state-of-the-art facilities for comprehensive research on factors driving obesity, opened to Clinical Center and NIH staff
You are here. Home » News & Events » 2006. In Drug Design, a Loose Fit May Be Best Bet